facebook
twitter
search
search

Supreme Court to take drug pricing case

Dec. 8, 2012 at 2:56 PM

WASHINGTON, Dec. 8 (UPI) -- The U.S. Supreme Court said it will rule in a case involving payments by pharmaceutical companies to rivals in return for delaying sales of generic drugs.

The Federal Trade Commission says the so-called pay-for-delay deals violate antitrust law, preserve monopolies and artificially jack up prices, the Los Angeles Times said Saturday.

The commission said 28 such agreements cost consumers and taxpayers at least $3.5 billion in 2011, the newspaper reported.

"When drug companies agree not to compete, consumers lose," FTC Chairman Jon Leibowitz said.

Federal courts have upheld such deals in a number of cases, finding they constitute settlements of patent disputes.

The Supreme Court said Friday it would consider a case involving an agreement in which Solvay Pharmaceuticals Inc., which makes the testosterone booster AndroGel, agreed to pay Watson Pharmaceuticals Inc. more than $19 million a year in return for Watson's agreement to hold a competitive drug off the market until 2015.

Related UPI Stories
Latest Headlines
Trending Stories
N.H. primary polls open: Kasich, Sanders get early leads
5 Reasons why Denver Broncos won't be repeat champions
U.N. report: Syria's Assad guilty of 'inhuman' crimes, gruesome torture, deaths
On heels of E. coli outbreaks, Chipotle spending millions for new ingredient safeguards
Hugh Jackman shows photo of his latest skin cancer treatment